Arimidex anastrozole aromatase inhibitor regulatory update

The FDA granted Fast Track designation for AZN's Arimidex's supplementary NDA to treat post-menopausal women with early-stage breast cancer. Arimidex is approved in the U.S. as a first-line therapy fo...